Angiotensin type 1 receptor block age improves ischemic injury following transient focal cerebral ischemia

被引:77
作者
Hosomi, N
Nishiyama, A
Ban, CR
Naya, T
Takahashi, T
Kohno, M
Koziol, JA
机构
[1] Kagawa Univ, Sch Med, Div Stroke, Dept Internal Med 2, Miki, Kagawa 7610793, Japan
[2] Kagawa Univ, Sch Med, Dept Pharmacol, Kagawa 7610793, Japan
[3] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
关键词
cerebral ischemia; cerebral edema; angiotensin II; matrix metalloproteinases;
D O I
10.1016/j.neuroscience.2005.03.054
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Following cerebral ischemia, i.v. infusion of angiotensin 11 increases cerebral edema and mortality. Angiotensin type 1 receptor blockage should therefore improve acute cerebral ischemia. Left middle cerebral artery occlusion (120 min) followed by reperfusion was performed with the thread method under halothane anesthesia in Sprague-Dawley rats. Olmesartan (angiotensin type 1 receptor blocker; 0.01 or 0.1 mu mol/ kg/h) was infused i.p. for 7 days following middle cerebral artery occlusion followed by reperfusion. Stroke index score, infarct volume, specific gravity, and brain angiotensin 11 and matrix metalloproteinases were quantified in the ischemic and non-ischemic hemispheres. Olmesartan treatment improved stroke index score, infarct volume, and cerebral edema in our cerebral ischemia model. In particular, stroke index score, infarct volume, and cerebral edema were reduced even with a low dose of olmesartan that did not decrease blood pressure. Paralleling these effects on cerebral ischemia, olmesartan treatment also reduced the reactive upregulation in brain angiotensin 11, matrix metalloproteinase-2, matrix metalloproteinase-9, and membrane type 1-matrix metalloproteinase in the ischemic area. Angiotensin type 1 receptor stimulation may be one of the important factors that cause cerebral edema following cerebral ischemia, and that its inhibition may be of therapeutic advantage in cerebral ischemia. (c) 2005 Published by Elsevier Ltd on behalf of IBRO.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 25 条
[1]  
ANDERSEN S, 1994, NORDISK ALKOHOL TIDS, V11, P31
[2]   Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats [J].
Ando, H ;
Zhou, J ;
Macova, M ;
Imboden, H ;
Saavedra, JM .
STROKE, 2004, 35 (07) :1726-1731
[3]   Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-α [J].
Arenas, IA ;
Xu, Y ;
Lopez-Jaramillo, P ;
Davidge, ST .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2004, 286 (04) :C779-C784
[4]   Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity [J].
Cipollone, F ;
Fazia, M ;
Iezzi, A ;
Pini, B ;
Cuccurullo, C ;
Zucchelli, M ;
de Cesare, D ;
Ucchino, S ;
Spigonardo, F ;
De Luca, M ;
Muraro, R ;
Bei, R ;
Bucci, M ;
Cuccurullo, F ;
Mezzetti, A .
CIRCULATION, 2004, 109 (12) :1482-1488
[5]   The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats [J].
Engelhorn, T ;
Goerike, S ;
Doerfler, A ;
Okorn, C ;
Forsting, M ;
Heusch, T ;
Schulz, T .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2004, 24 (04) :467-474
[6]   Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia [J].
Gasche, Y ;
Copin, JC ;
Sugawara, T ;
Fujimura, M ;
Chan, PH .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, 21 (12) :1393-1400
[7]   MICROVASCULAR BASAL LAMINA ANTIGENS DISAPPEAR DURING CEREBRAL-ISCHEMIA AND REPERFUSION [J].
HAMANN, GF ;
OKADA, Y ;
FITRIDGE, R ;
DELZOPPO, GJ .
STROKE, 1995, 26 (11) :2120-2126
[8]   Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion [J].
Hosomi, N ;
Lucero, J ;
Heo, JH ;
Koziol, JA ;
Copeland, BR ;
del Zoppo, GJ .
STROKE, 2001, 32 (06) :1341-1348
[9]   Induced hypertension treatment to improve cerebral ischemic injury after transient forebrain ischemia [J].
Hosomi, N ;
Mizushige, K ;
Kitadai, M ;
Ohyama, H ;
Ichihara, SI ;
Takahashi, T ;
Matsuo, H .
BRAIN RESEARCH, 1999, 835 (02) :188-196
[10]  
Kim S, 2003, AATCC REV, V3, P23